％0期刊论文％一关，卫杰％阿亮，文华％A照，易％阿亮，恒锐％阿陈，梓盛％A李易敏％A柳，Xiao-清％阿陈，汝庄％A唐春利％A王滔％A欧，春全％A锂，李％阿陈，平欣％A桑，凌％A王，魏％一立，建辅％A李，蔡辰％A欧，利民％阿城，博％A熊，山％A倪，郑毅％阿翔，捷％A胡，A刘裕％雷％A山，洪％阿磊，纯良％阿朋，宜香％阿伟，A刘丽％，雍％A胡锦涛，雅华％A彭，彭％A王，建明％A刘霁阳％阿陈，钟％A李岗％阿正，志坚％A秋，邵琴％罗，捷％爷，常江％A朱，邵勇％阿城，林龄％A烨，冯％A李，施跃％阿正，金平％A章，傩福％阿忠，南山％A他，建星％A，％T合并症并用COVID-19在中国其对1590名患者的影响：在全国范围内分析％d 2020％R 10.1183 / 13993003.00547-2020％Ĵ欧洲呼吸杂志％P 2000547％V 55％N 5％X背景冠状病2019（COVID-19）outbreak的快速发展worldwide.Objective要通过分层的合并症status.Methods我们分析的数据来自1590例实验室确认的31个省/自治区/直辖市省级整个住院的病人从医院575评估严重不良后果的风险，患者COVID-1912月11日到2020年一月期间2019 31中国大陆我们分析了复合终点，其中包括入院到重症监护病房，有创通气或死亡。The risk of reaching the composite end-points was compared according to the presence and number of comorbidities.Results The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities.Conclusion Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.The presence and number of comorbidities predict clinical outcomes of COVID-19 http://bit.ly/3b9ibw5 %U //www.qdcxjkg.com/content/erj/55/5/2000547.full.pdf